Go to journal home page - Clinical Genitourinary Cancer

Clinical Genitourinary Cancer

Volume 22, Issue 1

Pages 1-106 (February 2024)

Actions for selected articles


Receive an update when the latest issues in this journal are published
Sign in to set up alerts
  1. Differences in Survival of Clear Cell Metastatic Renal Cell Carcinoma According to Partial vs. Radical Cytoreductive Nephrectomy

    Pages 1-6
  2. The Impact of Prostate Volume in Open Radical Prostatectomy: A Single Centre Experience

    Pages 7-13
  3. The Impact of an Enrolment in Clinical Trial on Tolerance and Pathological Response for Patients Treated by Neoadjuvant MVAC Against an Invasive Bladder Cancer. A Retrospective Comparative Study

    Pages e14-e21.e3
  4. A SEER-Medicare Based Quality Score for Patients With Metastatic Upper Tract Urothelial Carcinoma

    Pages 14-22
  5. Case Series of Men with the Germline APC I1307K variant and Treatment-Emergent Neuroendocrine Prostate Cancer

    Pages e31-e37.e1
  6. Profiling of Serum miRNAs Constructs a Diagnostic 3-miRNA Panel for Clear-Cell Renal Cell Carcinoma

    Pages 23-32
  7. Testicular Radiomics To Predict Pathology At Time of Postchemotherapy Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Tumor

    Pages 33-37
  8. Neoadjuvant Chemotherapy Prior to Radical Cystectomy for Muscle-Invasive Bladder Cancer With Variant Histology: A Systematic Review and Meta-Analysis of Survival Outcomes and Pathological Features

    Pages e53-e65.e1
  9. Demographic Patterns and Clinicopathological Analysis of Sarcomatoid Renal Cell Carcinoma in US Population

    Pages 38-46
  10. A territory-wide real-world efficacy and toxicity analysis of abiraterone acetate versus docetaxel in 574 Asian patients with metastatic hormone-sensitive prostate cancer

    Pages e75-e85.e1
    View PDF
  11. Addition of Cribriform and Intraductal Carcinoma Presence to Prostate Biopsy Reporting Strengthens Pretreatment Risk Stratification Using CAPRA and NCCN Tools

    Pages 47-55
  12. Docetaxel Provides Oncological Benefits in the Era of New-Generation Androgen Receptor Inhibitors - or Is Three a Crowd?

    Pages 56-66
  13. Insulin-like Factor 3, Basal and Human Chorionic Gonadotropin-Stimulated Testosterone as Biomarkers to Predict the Effect of Testosterone Replacement in Testicular Cancer Survivors With Mild Leydig Cell Insufficiency

    Pages e106-e112.e4
    View PDF
  14. Clinical Presentation and Targeted Interventions in Urachal Adenocarcinoma: A Single-Institution Case Series and Review of Emerging Therapies

    Pages 67-75
  15. Adverse Events of Cabozantinib Plus Nivolumab Versus Ipilimumab Plus Nivolumab

    Pages e122-e127.e1
  16. Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab: A Multicenter Retrospective Study

    Pages 76-83
  17. Real-World Analysis of Treatment Patterns and Platinum-Based Treatment Eligibility of Patients With Metastatic Urothelial Cancer in 5 European Countries

    Pages e136-e147.e1
    View PDF
  18. Prostate Cancer Disparities in Metastatic and Treatment Status for Hispanic Americans Based on Country of Origin Compared to Non-Hispanic Whites Using the National Cancer Database

    Pages e148-e155.e1
  19. Urinary miRNAs Predict Metastasis in Patients With Clinically Localized Clear Cell Renal Cell Carcinoma Treated With Nephrectomy

    Pages e156-e162.e4
  20. The Molecular, Immunologic, and Clinicodemographic Landscape of MYC-Amplified Advanced Prostate Cancer

    Pages e163-e169.e1
  21. Cabozantinib in the Routine Management of Renal Cell Carcinoma: A Systematic Literature Review of Real-World Evidence

    Pages 84-97
    View PDF
  22. Epidemiology, Management, and Survival Outcomes of Germ Cell Cancer in Southern Portugal: A Population-Based Study (2008-2012)

    Pages e170-e177.e1
  23. Do Urine Cytology and FISH Analysis Have a Role in the Follow-Up Protocol of Upper Tract Urothelial Carcinoma?

    Pages 98-105

ISSN: 1558-7673